News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Philadelphia-based Cancer Research Institutions Receive over $700M in National Cancer Institute Grants from 2019 to 2021, Fourth-most in the Nation
The University of Pennsylvania led the region with 490 NCI grants totaling $234 million during this three year time period.
Local Startups Participate in Pennovation Accelerator Program
Learn about the cohort of local startups participating in the fifth annual Pennovation Accelerator.
Philadelphia Ranked as One of the Top Startup Ecosystems in the United States
Startup Genome described Philly as "a vibrant Life Science hub and a particularly attractive home base for female entrepreneurs."
Penn Welcomes Ninth President to Campus
The Penn community gathered on College Green to welcome the new president.
Penn researchers invent microrobots to brush teeth
In a proof-of-concept study, a robotic microswarm of nanoparticles, arranged in bristle-like structures, effectively cleaned plaque and decay-causing bacteria from both mock and human teeth.
Press Highlights of FY22
During the 2022 fiscal year, there were 98 press mentions for PCI programs, startups and partners. Some of the most popular and widely circulated stories are included here.
Peroxitech raises $25M Series A
PCIV startup Peroxitech Inc. announced the successful completion of a $25M Series A financing for treatment of acute lung injury (ALI) into clinical development.
Penn Engineering Lab develops next-generation drug delivery technologies
Mike Mitchell's lab has numerous ongoing research partnerships to support new therapeutic solutions with commercial entities that were facilitated by PCI.
Philadelphia Cell and Gene Therapy Jobs More Than Doubled in Less Than Three Years
As the number of gene and cell therapy jobs continue to grow, Philadelphia continues to attract diverse pools of talent.
Penn spinout Verismo Therapeutics Makes Agreement to Fund University Research of KIR-CAR platform of Car-T to Target Solid Tumors
Learn about Penn spinout Verismo Therapeutics' agreement to fund four years of university research of KIR-CAR platform of Car-T to target solid tumors.